Maintaining complete virological suppression by reduced doses of nucleos(t)ide analogue in patients with chronic hepatitis B

Journal of Medical Virology
Chao-Wei HsuChau-Ting Yeh

Abstract

In patients with chronic hepatitis B (CHB), withdrawal of nucleos(t)ide analogues (NAs) can put patients at risk of hepatitis relapses. Here, we examined a dose-reducing strategy. From March 2008 to September 2016, 48 patients with CHB who had received full-dose NA (35 entecavir; 13 tenofovir) and achieved complete virological response (lasting for >1 year), were placed on a reduced dose of antivirals (twice a week) subsequently. In a median follow-up period of 33.2 months, only one patient experienced a virological but not biochemical breakthrough. No deterioration of estimated glomerular filtration rate was found. This strategy could be used in areas where full dose, lifelong treatment is unachievable.

References

Feb 17, 2009·Lancet·Yun-Fan Liaw, Chia-Ming Chu
Jan 5, 2017·Liver International : Official Journal of the International Association for the Study of the Liver·Chern Hao Chong, Seng Gee Lim
Aug 5, 2017·Best Practice & Research. Clinical Gastroenterology·Marc G Ghany
Feb 11, 2018·Liver International : Official Journal of the International Association for the Study of the Liver·Sebastián Marciano, Adrián Gadano

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.